☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
p-iv
Eli Lilly Reports Results of Taltz (ixekizumab) in Head-to-Head P-IV IXORA-R Study for Moderate to Severe Plaque Psoriasis
October 3, 2019
Novartis Reports Results of Galvus (vildagliptin) Combination Therapy in P-IV VERIFY Study for Type 2 Diabetes Mellitus
September 19, 2019
Eli Lilly Reports Superiority Results of Taltz (ixekizumab) in P-IV IXORA-R Study for Patients with Moderate to Severe Plaque Psor...
August 13, 2019
BMS Reports Results of Orencia (abatacept) in P-IV Early AMPLE Study for Moderate-to-Severe Rheumatoid Arthritis #EULAR2019
June 14, 2019
Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men
May 6, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.